ARMGO Pharma, Inc. is a biopharmaceutical company that develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. Their flagship product, Rycals, are calcium release channel stabilizers that target the ryanodine receptor/calcium release channel. These therapeutics have potential applications in treating chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, and other conditions.

Helen Wu

Andrew Marks

ARMGO Pharma, Inc.

ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. 

Our primary focus is on two orphan diseases:  the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. 

ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.

Kurma Partners

Pontifax

Forbion Capital Partners

Attending the American Heart Association's Scientific Sessions 2023 in Philadelphia?
 
Our CEO Gene Marcantonio and our Medical Director Yigal Pinto will be on site to discuss world-leading science and to meet cardiologists as well as pharma industry.

On Saturday November 11, make sure to stop by board no. 2272 to gain insight into an innovative #biomarker study in #heartfailure presented by an expert team from Amsterdam UMC and Henry Ford Health led by Yigal.
 
Want to learn more but aren't attending the event? Reach out via our website to schedule time to meet with a member of our team: https://lnkd.in/d23wB3Dv

Meet our team at Proventa International's Medicinal Chemistry Strategy Meeting!
 
Next week, ARMGO's Chief Operating Officer and General Counsel, Yael Webb, Ph.D., J.D. Webb is heading to #Boston to join professionals from across the field of medicinal chemistry as they discuss this year's event theme - 'Reinvigorating Productivity in #Pharma & #Biotech R&D'.
 
Get in contact via our website to schedule a meeting at the event: https://lnkd.in/d23wB3Dv

We are excited to be here in Basel, Switzerland, for the second day of the Sachs 23rd Annual Biotech in Europe Forum.

Yesterday, ARMGO’s Vice President of Business Development, Hermann-Josef Kaiser, took part in a panel alongside #industry experts from EQT Life Science, Cardior Pharmaceuticals GmbH, Neurimmune AG and Bayer AG. The session, ‘The Heart is in Again – Are We Seeing a Renaissance of Cardiovascular & Cardiometabolic Panel’ provided critical insight into the latest wave of innovations and regulatory challenges to develop new therapeutics for #heartdisease.

In a separate session Hermann also presented ARMGO’s novel small molecule therapeutics, Rycals, as well as an update on the #phase2 #clinicaltrial to treat the life threatening #arrhythmia, Catecholaminergic Polymorphic Ventricular Tachycardia (#CPVT).

Want to learn more? Visit our website for more information, or use the contact form to schedule a meeting with one of our team: https://www.armgo.com

#Sachs_BEF

Meet our team at the Sachs 23rd Annual Biotech in Europe Forum!

ARMGO’s Vice President of Business Development, Hermann-Josef Kaiser, will be in Basel from the 20 – 21 September to join a panel discussion with other pharma and biotech leaders on therapeutic innovation in cardiovascular disorders. 

In addition, he is a speaker at the event. His talk will provide insight into ARMGO’s novel small molecule therapeutics, Rycals, as well as our #phase2 #clinicaltrial to investigate lead molecule ARM210 as a treatment of the life threatening #arrhythmia, Catecholaminergic Polymorphic Ventricular Tachycardia (#CPVT). 

Want to learn more? Visit our website for more information, or use the contact form to schedule a meeting with one of our team: https://www.armgo.com

#Sachs_BEF

Each year, the European Society of Cardiology honors exceptional cardiologists with its ESC Gold Medal, recognizing outstanding achievement. 

ARMGO is delighted to congratulate world expert in #heartdisease, Professor Arthur Wilde, University of Amsterdam on receiving the award. ARMGO thanks Prof. Wilde for his crucial role as a Principal Investigator in ARMGO’s #phase2 #clinicaltrial for the #treatment of rare genetic #arrhythmia Catecholaminergic Polymorphic Ventricular Tachycardia (#CPVT). 

The award has been announced on Friday at the #ESCcongress in Amsterdam. If you’re interested in learning more about the trial and how we are addressing the challenges of heart disease, reach out via our website: https://lnkd.in/d23wB3Dv

Metric
Company Name	ARMGO Pharma, Inc.
Symbol
MSH ID	COM:ARMGO
Market	PRIVATE
Sector	Healthcare
Industry	Biopharmaceuticals
Country	US
Stage
Employee Count	9
Website	armgo.com
LinkedIn	armgo-pharma-inc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ARMGO

ARMGO Pharma, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue